Jennifer R. Tall

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

Erratum: Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

Erratum: Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

Journal: JCO precision oncology
Published: July 16, 2026

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

Frequency and Prognostic Significance of Genetic Abnormalities in a Subgroup of Patients With Intermediate-Risk Neuroblastoma: A SIOPEN Study.

Journal: JCO precision oncology
Published: July 01, 2026

Human DEAH-box helicase 8 regulates HSF1-mediated stress response and cancer-associated pre-mRNA splicing in tumour cells.

Human DEAH-box helicase 8 regulates HSF1-mediated stress response and cancer-associated pre-mRNA splicing in tumour cells.

Journal: NAR cancer
Published: September 25, 2025

Diagnostic technologies for neuroblastoma.

Diagnostic technologies for neuroblastoma.

Journal: Lab on a chip
Published: July 14, 2025

ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma.

ATRX mutations mediate an immunogenic phenotype and macrophage infiltration in neuroblastoma.

Journal: Cancer letters
Published: November 07, 2024

Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.

Stratified Medicine Pediatrics: Cell-Free DNA and Serial Tumor Sequencing Identifies Subtype-Specific Cancer Evolution and Epigenetic States.

Journal: Cancer discovery
Published: June 27, 2024

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.

Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.

Journal: EBioMedicine
Published: May 22, 2020

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

Journal: Molecular oncology
Published: December 16, 2016

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Journal: Pediatric blood & cancer
Published: May 18, 2016
Showing 1-9 of 9

Last Updated: 09/26/2026